Reducing prostaglandin E2 production to raise cancer immunogenicity.
Name:
Reducing prostaglandin E2 ...
Size:
1.114Mb
Format:
PDF
Description:
Open access full text article
Affiliation
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester , ManchesterIssue Date
2016-05
Metadata
Show full item recordAbstract
Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E2 (PGE2), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE2 by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication.Citation
Reducing prostaglandin E2 production to raise cancer immunogenicity. 2016, 5 (5):e1123370 OncoimmunologyJournal
OncoimmunologyDOI
10.1080/2162402X.2015.1123370PubMed ID
27467936Type
ArticleLanguage
enISSN
2162-4011ae974a485f413a2113503eed53cd6c53
10.1080/2162402X.2015.1123370
Scopus Count
Collections
Related articles
- Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells.
- Authors: Jin K, Qian C, Lin J, Liu B
- Issue date: 2023
- Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ--prostaglandin E2 dependent proliferation of growth plate chondrocytes.
- Authors: Brochhausen C, Neuland P, Kirkpatrick CJ, Nüsing RM, Klaus G
- Issue date: 2006
- Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.
- Authors: Liu B, Qu L, Yan S
- Issue date: 2015
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.
- Authors: Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C
- Issue date: 2015 Sep 10
- Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer.
- Authors: Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, Li Y, Zhou Q, Li L
- Issue date: 2021